Search…

Lizhu Pharmaceutical (01513.HK) announced its half-year performance with a net profit attributable to shareholders of 1.281 billion yuan, an increase of 9.4% year-on-year.

20/08/2025

The Zhitong Financial APP reported that Li Zhu Pharmaceutical (01513.HK) released its performance for the first half of 2025, with operating income of approximately 6.272 billion yuan, a decrease of 0.17% year-on-year; net profit attributable to shareholders of the listed company was approximately 1.281 billion yuan, an increase of 9.4% year-on-year; basic earnings per share were 1.43 yuan.

Latest

2 m ago

Analysts Wade Bush stated that as the application scenarios of artificial intelligence continue to expand, Nvidia's quarterly report released on August 27 will become the next important investment catalyst. The institution believes that the market is currently in the initial stage of several years of AI infrastructure construction and sees this financial report as an important confirmation of this cycle.

2 m ago

Analysts at Wade Bush stated that as the application scenarios of artificial intelligence continue to expand, the quarterly report released by NVIDIA on August 27th will become the next important investment catalyst. The institution believes that the market is in the early stages of several years of AI infrastructure construction and views this financial report as an important confirmation of this cycle.

4 m ago

The Financial Regulatory Bureau plans to broaden the scope of application of merger and acquisition loans.

6 m ago

Russian trade officials said this week that despite the threat of deep impact from US tariffs, it is unlikely that India's import of Russian crude oil will decrease.

9 m ago

Unusual movement in US stocks | Medtronic (MDT.US) rises over 4% as Q1 FY2026 results exceed expectations and full-year profit guidance is increased.

See all latest